Advertisement

Genitourinary Oncology

Prostate, Renal, and Bladder Cancer
  • Robert Dreicer
Part of the Current Clinical Oncology book series (CCO)

Abstract

Among the major genitourinary neoplasms, prostate and renal cell carcinomas rank high among all epithelial neoplasms in the relative incidence of both bone metastases and spinal cord compression (1,2). Although advanced urothelial cancers (primarily bladder cancer) represent a relatively small number of patients, this neoplasm too has a relatively high predilection to spread to bone (3). Although the fundamental management issues of skeletal metastases are similar within these neoplasms, the systemic therapies utilized to treat these diseases are very different; hormonal therapy for prostate cancer, immunotherapy for renal cell cancer, and systemic chemotherapy for advanced urothelial cancers. The relative effectiveness of these diverse therapies impact on some important aspects of the management of metastatic disease to the spine in patients with these neoplasms.

Keywords

Prostate Cancer Bladder Cancer Bone Metastasis Clin Oncol Spinal Cord Compression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sioutos PJ, Arbit E, Meshulam CF, Galicich JH. Spinal metastases from solid tumors. Analysis of factors affecting survival. Cancer 1995; 76:1453–1459.PubMedCrossRefGoogle Scholar
  2. 2.
    Ratanatharathorn V, Powers WE. Epidural spinal cord compression from metastatic tumor: diagnosis and guidelines for management. Cancer Treat Rev 1991; 18:55–71.PubMedCrossRefGoogle Scholar
  3. 3.
    Sengelov L, Kamby C, von der maase H. Pattern of metastases in relation to characteristics of primary tumor and treatment in patients with disseminated urothelial carcinoma. J Urol 1996; 155:111–114.PubMedCrossRefGoogle Scholar
  4. 4.
    Jemal A, Murray T, Ward E, et al. Cancer Statistics 2005. CA Cancer J Clin 2005; 55:10–30.PubMedCrossRefGoogle Scholar
  5. 5.
    Nwosu V, Carpten J, Trent JM, Sheridan R. Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. Hum Mol Genet 2001; 10:2313–2318.PubMedCrossRefGoogle Scholar
  6. 6.
    Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992; 89:3367–3371.PubMedCrossRefGoogle Scholar
  7. 7.
    Bratt O. Hereditary prostate cancer. BJU Int 2000; 85:588–598.PubMedCrossRefGoogle Scholar
  8. 8.
    Ross RK, Pike MC, Coetzee GA, et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 1998; 58:4497–4504.PubMedGoogle Scholar
  9. 9.
    Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate specific antigen. JAMA 1996; 276:1309–1315.PubMedCrossRefGoogle Scholar
  10. 10.
    Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy: patterns of recurrence and cancer control. Urol Clin North Amer 1997; 24:395–406.CrossRefGoogle Scholar
  11. 11.
    Laufer M, Pound CR, Carducci MA, Eisenberger MA. Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology 2000; 55:309–315.PubMedCrossRefGoogle Scholar
  12. 12.
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281:1591–1597.PubMedCrossRefGoogle Scholar
  13. 13.
    Lytton B. Prostate cancer: a brief history and the discovery of hormonal ablation treatment. J Urol 2001; 165:1859–1862.PubMedCrossRefGoogle Scholar
  14. 14.
    Dreicer R. The evolving role of hormone therapy in advanced prostate cancer. Cleve Clin J Med 2000; 67:720–722.PubMedGoogle Scholar
  15. 15.
    Peeling WB. Phase III studies to compare Goserelin (Zoladex) with Orchiectomy and with Diethylstilbestrol in treatment of prostatic carcinoma. Urology 1989; 33:45–52.PubMedCrossRefGoogle Scholar
  16. 16.
    Maatman TJ, Gupta MK, Montie JE. Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate. J Urol 1985; 133:620–621.PubMedGoogle Scholar
  17. 17.
    Whitmore WF. Natural history and staging of prostate cancer. Urol Clin North Am 1984; 11:209–220.Google Scholar
  18. 18.
    Galasko CSB. The anatomy and pathways of skeletal metastases. In: Weiss L, Gilbert HA, eds. Bone Metastasis. Boston, MA: Hall Medical Publishers; 1981:49–63.Google Scholar
  19. 19.
    Garnero P. Markers of bone turnover in prostate cancer. Cancer Treat Rev 2001; 27:187–192.PubMedCrossRefGoogle Scholar
  20. 20.
    Batson OV. The function of the vertebral veins and their role in the spread of metastases. Ann Surg 1940; 112:138–149.PubMedCrossRefGoogle Scholar
  21. 21.
    Chen TC. Prostate cancer and spinal cord compression. Oncology 2001; 15:841–855.PubMedGoogle Scholar
  22. 22.
    Kuban DA, el-Mahdi AM, Sigfred SV, Schellhammer PF, Babb TJ. Characeristics of spinal cord compression in carcinoma of the prostate. Urology 1986; 28:364–369.PubMedCrossRefGoogle Scholar
  23. 23.
    Bayley A, Milosevic M, Blend R, et al. A prospective study of factors predicting clinically occult spinal cord compression in patients with metastatic prostate carcinoma. Cancer 2001; 92:303–310.PubMedCrossRefGoogle Scholar
  24. 24.
    Osborn JL, Getzenberg RH, Trump DL. Spinal cord compression in prostate cancer. J Neurooncol 1995; 23:135–147.PubMedCrossRefGoogle Scholar
  25. 25.
    Oesterling JE, Martin SK, Bergstralh EJ Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993; 269:57–60.PubMedCrossRefGoogle Scholar
  26. 26.
    Wong DA, Fornasier VL, MacNab I. Spinal metastases: the obvious, the occult and the imposters. Spine 1990; 15:1–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Posner JB. Neurologic complications of cancer. In: Davis FA, ed. Contemporary Neurology Series. Philadelphia, PA: FA Davis; 1995:122.Google Scholar
  28. 28.
    Catton CN, Gospodarowicz MK. Palliative radiotherapy in prostate cancer. Sem Urol Oncol 1997; 15:65–72.Google Scholar
  29. 29.
    Tannock IF. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 1985; 3:1013–1021.PubMedGoogle Scholar
  30. 30.
    Tannock IF, Osaba D, Stackler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14:1756–1764.PubMedGoogle Scholar
  31. 31.
    Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17:2506–2513.PubMedGoogle Scholar
  32. 32.
    Tannock I, de Wit R, Berry W, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502–1512.PubMedCrossRefGoogle Scholar
  33. 33.
    Petrylak D, Tangen C, Hussain M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513–1520.PubMedCrossRefGoogle Scholar
  34. 34.
    McEwan AJB. Unsealed source therapy of painful bone metastases: an update. Semin Nucl Med 1997; 27:165–182.PubMedCrossRefGoogle Scholar
  35. 35.
    Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001; 357:336–341.PubMedCrossRefGoogle Scholar
  36. 36.
    Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999; 281:1628–1631.PubMedCrossRefGoogle Scholar
  37. 37.
    Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001; 166:1611–1623.PubMedCrossRefGoogle Scholar
  38. 38.
    Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260:1317–1320.PubMedCrossRefGoogle Scholar
  39. 39.
    Shuin T, Kondo K, Torigoe S, et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994; 54:2852–2855.PubMedGoogle Scholar
  40. 40.
    Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335:865–875.PubMedCrossRefGoogle Scholar
  41. 41.
    Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163:408–417.PubMedCrossRefGoogle Scholar
  42. 42.
    Figlan RA. Renal cell carcinoma: management of advanced disease. J Urol 1999; 161:381–387.CrossRefGoogle Scholar
  43. 43.
    Bukowski RM. Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol 2001; 19:148–154.PubMedGoogle Scholar
  44. 44.
    Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 1993; 20:283–295.PubMedGoogle Scholar
  45. 45.
    Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted in renal cell carcinoma. J Clin Oncol 2005; 23:1028–1043.PubMedCrossRefGoogle Scholar
  46. 46.
    Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345:1655–1659.PubMedCrossRefGoogle Scholar
  47. 47.
    Mickisch GHJ, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358:966–970.PubMedCrossRefGoogle Scholar
  48. 48.
    Saitoh H, Hida M. Metastatic processes and a ptoetnital indication of treatment for metastatic lesions of renal adenocarcinoma. J Urol 1982; 128:916–918.PubMedGoogle Scholar
  49. 49.
    Skinner DG, Colvin RB. Diagnosis and management of renal cell carcinoma: a clinical and pathological study. Cancer 1971; 28:1165–1177.PubMedCrossRefGoogle Scholar
  50. 50.
    Swanson DA, Orovan WL, Johnson DE, Giacco G. Osseous metastases secondary to renal cell carcinoma. Urology 1981; 18:556–561.PubMedCrossRefGoogle Scholar
  51. 51.
    Liskow A, Chang CH, Desanctis P, Benson M, Fetell M, Housepian E. Epidural cord compression in association with genitourinary neoplasms. Cancer 1986; 58:949–954.PubMedCrossRefGoogle Scholar
  52. 52.
    Seitz W, Karcher KH, Binder W. Radiotherapy of metastatic renal cell carcinoma. Sem Surg Oncol 1988; 4:100–102.Google Scholar
  53. 53.
    DiBiase SJ, Valicenti RK, Schultz D, Xie Y, Gomella LG, Corn BW. Palliative irradiation for focally sumptomatic metastatic renal cell carcinoma: support for dose escalation based on a biological model. J Urol 1997; 158:746–749.PubMedCrossRefGoogle Scholar
  54. 54.
    Jackson RJ, Gokaslan ZL, Loh SC. Metastatic renal cell carcinoma of the spine: surgical treatment and results. J Neurosurg 2001; 94:18–24.PubMedGoogle Scholar
  55. 55.
    Baumgart J, Zhukovskaya NV, Anisimov VN. Carcinogenesis and aging. VIII. Effect of host age on tumour growth, metastatic potential, and chemotherapeutic sensitivity to 1.4-benzoquinoneguanylhydrazonethiosemicarbazone (ambazone) and 5-fluorouracil in mice and rats. Exp Pathol 1988; 33:239–248.PubMedGoogle Scholar
  56. 56.
    Silverman DT, Levin LI, Hoover RN, et al. Occupational risks of bladder cancer in the United States: I. White men. J Natl Cancer Inst 1989; 81:1472–1480.PubMedCrossRefGoogle Scholar
  57. 57.
    Ross RK, Jones PA, MC Y. Bladder cancer epidemiology and pathogenesis. Sem Oncol 1996; 23:536–545.Google Scholar
  58. 58.
    Kryger JV, Messing E. Bladder cancer screening. Sem Oncol 1996; 23:585–597.Google Scholar
  59. 59.
    Vaughn DJ, Malkowicz SB. Recent advances in bladder cancer chemotherapy. Cancer Invest 2001; 19:77–85.PubMedCrossRefGoogle Scholar
  60. 60.
    Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997; 15:2564–2569.PubMedGoogle Scholar
  61. 61.
    Dreicer R. Locally advanced and metastatic bladder cancer. Curr Treat Options Oncol 2001; 2:431–436.PubMedCrossRefGoogle Scholar
  62. 62.
    Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17:3173–3181.PubMedGoogle Scholar
  63. 63.
    Medical Research Council Renal Cancer Collaborators.: Interferon-a and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999; 353:14–17.CrossRefGoogle Scholar
  64. 64.
    Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17:2859–2867.PubMedGoogle Scholar
  65. 65.
    Gleave ME, Elhilali M, Fradet Y, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 1998; 338:1265–1271.PubMedCrossRefGoogle Scholar
  66. 66.
    Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998; 338:1272–1278.PubMedCrossRefGoogle Scholar
  67. 67.
    Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1992; 10:1066–1073.PubMedGoogle Scholar
  68. 68.
    Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8:1050–1055.PubMedGoogle Scholar
  69. 69.
    von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrextate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18:3068–3077.PubMedGoogle Scholar

Copyright information

© Humana Press, Inc., Totowa, NJ 2006

Authors and Affiliations

  • Robert Dreicer
    • 1
  1. 1.Genitourinary Medical Oncology and Experimental Therapeutics, Department of Hematology/Oncology and the Urologic InstituteThe Cleveland Clinic FoundationCleveland

Personalised recommendations